GH Research PLC
Clinical-stage biopharma developing mebufotenin therapies for psychiatric disorders.
GHRS | NDAQ
Overview
Corporate Details
- ISIN(s):
- IE000GID8VI0
- LEI:
- Country:
- United States of America
- Address:
- JOSHUA DAWSON HOUSE, DUBLIN 2
- Website:
- http://www.ghres.com
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. The company develops novel therapies based on its proprietary mebufotenin (5-MeO-DMT) platform. Its lead product candidate, GH001, is an inhaled formulation of mebufotenin in clinical development for Treatment-Resistant Depression (TRD). The pipeline also includes programs for Bipolar II Disorder and Postpartum Depression. GH Research aims to provide treatments with faster onset of action, increased remission rates, durable effects, and improved tolerability, supported by a growing portfolio of intellectual property covering various aspects of mebufotenin's therapeutic use.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all GH Research PLC filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for GH Research PLC
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for GH Research PLC via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
